This article is more than 5 years old. Information may no longer be current.

Genotypic expression of VEGF gene sites may determine success of PDT for AMD

Ophthalmology. 2010;117(1):103-108.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Genetics may play a role in how patients with age-related macular degeneration respond to photodynamic therapy.

In a study analyzing three distinct single nucleotide polymorphisms (SNPs) on the gene coding for VEGF — an A to C substitution at rs699947, an A to C substitution at rs2146323, and an A to G substitution at rs3025033 — none of the SNPs were associated with the presence of exudative AMD.

However, among 86 patients who underwent PDT, frequencies of genotypic expressions of two of the designated SNPs varied significantly. According to the study, the AA, AC and CC genotypes of rs699947 were noted in 14%, 39% and 46% of patients, respectively, who did not respond to PDT, compared with 40%, 48% and 12% of patients who demonstrated anatomic resolution of exudation on fluorescein angiography.

Similarly, the AA, AC and CC genotypes of rs2146323 were noted in 4%, 32% and 64% of patients who failed therapy and 24%, 38% and 38% of patients who successfully completed therapy.